Pall Biotech focuses on end-to-end drug manufacturing technologies

Filtration, separation and purification specialist Pall Corporation has a newly named business unit within the Pall Life Sciences division. The Pall Biotech business unit has been named to reflect an important strategic direction for the company.

Pall says the update will not impact company operations. 

“As the lines between the biopharmaceutical and biotechnology sectors continue to merge, our commitment is stronger than ever to develop and deliver end-to-end capabilities with cutting-edge technologies and services," states Mario Philips, Vice President & General Manager of Pall Biotech. "The name Pall Biotech reflects a more focused approach to serving these high-growth market segments.”  

He says the new name also reflects Pall's our dedication to reducing costs, while increasing efficiency and quality, for developers of sensitive biologic products, including mAbs, recombinant proteins, viral vaccines, and cell and gene therapies.

The Pall Biotech portfolio of standard configurable single-use, stainless steel and hybrid technologies for fed-batch and continuous processes across upstream, downstream and formulation and filling applications is designed to enable customers to accelerate time to market.

The company's recently launched CadenceTM inline diafiltration (ILDF) was recognized as a 2017 innovation of the year by The Medicine Maker Innovation Awards.